- Report
- January 2026
- 150 Pages
Global
From €3590EUR$3,950USD£3,096GBP
- Report
- July 2025
- 150 Pages
Global
From €5408EUR$5,950USD£4,664GBP
- Report
- June 2026
- 182 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 189 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- June 2026
- 281 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- June 2026
- 364 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- May 2026
- 180 Pages
Global
From €4090EUR$4,500USD£3,527GBP
- Report
- March 2026
- 200 Pages
Global
From €2535EUR$2,789USD£2,186GBP
- Report
- January 2026
- 148 Pages
Global
From €3590EUR$3,950USD£3,096GBP
- Report
- October 2025
- 150 Pages
Global
From €4408EUR$4,850USD£3,802GBP
- Report
- August 2025
- 120 Pages
United States
From €3590EUR$3,950USD£3,096GBP
- Report
- November 2018
- 147 Pages
Global
From €2500EUR$2,750USD£2,156GBP
- Report
- December 2024
- 150 Pages
Global
From €5408EUR$5,950USD£4,664GBP
- Report
- October 2023
- 145 Pages
Global
From €2863EUR$3,150USD£2,469GBP
- Report
- October 2023
- 145 Pages
Global
From €2863EUR$3,150USD£2,469GBP
- Report
- November 2023
- 189 Pages
Global
From €4090EUR$4,500USD£3,527GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1818EUR$2,000USD£1,568GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2272EUR$2,500USD£1,960GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more